Drug Prices
- Virginia Congressman Suhas Subramanyam Discusses Working Relationships in Congress
Representative Suhas Subramanyam, a Democrat representing Virginia’s 10th Congressional District, has noted his capacity to work effectively with progressive members of his party. These include individuals associated with efforts to reform or eliminate certain federal immigration enforcement mechanisms. Subramanyam assumed office in January 2025 after serving in the Virginia House of Delegates and
- Governor Abigail Spanberger kills Prescription Drug Affordability Board proposal
A five-year effort to curb drug prices through a Prescription Drug Affordability Board just faced its third veto between two governors, as Abigail Spanberger formally rejected the measure Tuesday. The proposal had evolved over the years: first as a board to set payment limits on drug prices, and later as an advisory panel to help […]
- Governor pitches amendments to Prescription Drug Affordability Board bill that some say ‘nullify’ it
Photo illustration of prescription medicine in bottles. (Photo by Charlotte Rene Woods/Virginia Mercury) While Gov. Abigail Spanberger never signaled she would sign the proposed Prescription Drug Affordability Board, the bills’ patrons Del. Karrie Delaney, D-Fairfax, and Sen. Creigh Deeds, D-Charlottesville, had communicated with her during this year’s legislative session as they workshopped thei
- Abigail Spanberger signs first wave of bills targeting health care, housing and energy cost
Gov. Abigail Spanberger signing bills. (Photo by Charlotte Rene Woods/Virginia Mercury) Gov. Abigail Spanberger has signed the first first batch of bills passed by state lawmakers before they adjourned in mid-March, advancing measures on health care, housing and energy affordability. With hundreds of bills cleared by the legislature, she has until April 13 to sign, […]
- Trump signs order aiming to lower U.S. drug costs to match prices abroad
President Donald Trump signed an executive order Monday aimed at lowering drug prices by pressuring pharmaceutical companies to align their U.S. pricing models with those in similarly wealthy countries.